Arxx Therapeutics AS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arxx Therapeutics AS - overview
Established
2018
Location
Oslo, -, Norway
Primary Industry
Biotechnology
About
Based in Oslo, Norway, and founded in 2018 by co-founders Jorg Klingelhofer and Jonas Hallen, Arxx Therapeutics AS operates as a biopharmaceutical-based company providing medicine, drug development and molecular biology for patients suffering from fibrotic disease. In January 2024, Oxitope Pharma B. V. merged with Arxx Therapeutics AS, a portfolio company of Rasmussen Gruppen AS, Investinor, altitude Capital Management, Veen Eiendom AS, P53, Sarsia Management, Trond Mohn Stiftelsen, MP Pensjon, Asteroid Bakken AS and Andenes Investments, to form Calluna Pharma.
Arxx Therapeutics AS developed therapeutic strategies for Systemic sclerosis, which is an autoimmune disease that causes fibrosis and tissue dysfunction in human body organs. The company offers S100A4, that boosts the body and targets lesional tissue systemically in patients with SSc disease activity, skin fibrosis and pulmonary function. It created AX-202, which supports patients that ameliorate fibrosis in both inflammatory and non-inflammatory models of skin fibrosis.
Current Investors
Calluna Pharma AS, Sarsia, Investinor
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
http://www.arxxtx.com/
Company Stage
Merged
Total Amount Raised
Subscriber access only
Arxx Therapeutics AS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Completed | Arxx Therapeutics AS, Oxitope Pharma B.V. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.